Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Apr 10;19(7):1033–1039. doi: 10.1016/j.bbmt.2013.04.005

Table 1.

Conditioning regimens for case (CY/TBU) and control (TBU/CY) patients.a

CY/TBU Cases (n=51) TBU/CY Controls (n=271)
Conditioning agents, by transplant day
 -7 CY IV 60 mg/kgb BUc
 -6 CY IV 60 mg/kg TBU
 -5 BUc TBU
 -4 TBU TBU
 -3 TBU CY IV 60 mg/kgb
 -2 TBU CY IV 60 mg/kg
 -1 Rest Rest
 0 Allograft infusion Allograft infusion
Busulfan administration route & dosing frequency
 Oral every 6 hours 0 252 (93%)
 IV every 6 hours 0 15 (6%)
 IV once daily 51 (100%) 4 (1%)
Cumulative busulfan dose (mg)
 Oral Not applicable 1048 (572–1916)
 IV 1098 (580–1510) 976 (608–1668)
Target busulfan Css (ng/ml)
 ≤900d 0 2 (0.7%)
 600–900 0 3 (1.1%)
 800–900 51 (100%) 262 (96.7%)
 >900d 0 4 (1.5%)
Busulfan pharmacokinetics
 Dose #1 Css >900 ng/mL 23 (45%) 128 (47%)
 Average daily Csse >900 ng/mL 1 (2%) 18 (7%)
 Average daily Csse (ng/mL) 856 (811–1191) 861 (627–968)
a

Data presented as median (range) or number (%). Abbreviations: TBU, targeted busulfan; CY, cyclophosphamide; IV, intravenous; Css, busulfan steady-state concentration.

b

Mesna given concurrently with IV cyclophosphamide to prevent hemorrhagic cystitis.

c

Phenytoin started one day before busulfan and continued throughout busulfan administration (i.e., day -6 through day -1 for CY/TBU, and day -8 through day -3 for TBU/CY).

d

Specific target Css detailed in the busulfan dosing and pharmacokinetics section of text.

e

Cumulative over all 4 days of busulfan administration. For Css, each patient’s busulfan Css over all 4 days was calculated, and then divided by 4 to provide the average daily Css.